Skip to main content

Advertisement

Table 3 Number, level and volume of other Modic changes (MC) than the primary Modic changea at baseline and follow-up and the change in the volume according to treatment group

From: The effect of zoledronic acid on type and volume of Modic changes among patients with low back pain

Volume of other than the primary Modic changea Mean (SD) Mean (SD) change Unadjusted analyses
ZA Placebo ZA Placebo Difference (95% CI) Pb
Multiple MCs, n (%)
 At two levels 9 (60) 6 (75)     
 At three levels 6 (40) 2 (25)     
Level of the other than the primary MC, n (%)
 L1/2 1 (6.7) 0 (0.0)     
 L2/3 1 (6.7) 1 (12.5)     
 L3/4 2 (13.3) 0 (0.0)     
 L4/5 5 (33.3) 4 (50.0)     
 L5/S1 6 (40.0) 3 (37.5)     
Volume of M1a (cm3)
 Baseline 0.80 (1.92) 1.20 (1.62)     
 Follow-up 1.69 (2.50) 2.22 (2.20) 0.89 (2.23) 1.03 (2.21) −0.14 (−2.16, 1.89) 0.89
Volume of M2a (cm3)
 Baseline 6.98 (8.01) 4.36 (5.27)     
 Follow-up 6.49 (6.74) 3.93 (4.72) −0.49 (2.54) −0.43 (1.49) −0.06 (−2.10, 1.98) 0.95
Total volumea (cm3)
 Baseline 7.78 (8.49) 5.55 (5.36)     
 Follow-up 8.18 (7.75) 6.15 (5.24) 0.40 (1.09) 0.60 (1.53) −0.19 (−1.33, 0.95) 0.73
  1. SD standard deviation, CI confidence interval, ZA zoledronic acid
  2. aThe primary Modic change was assumed to cause patients’ symptoms at baseline
  3. bIndependent samples t-test for change in the volume between the treatment groups